Abstract
Drug development for obstetrics occurs via an informal process of migration from use in adults, irrespective of the therapeutic target; mother, placenta or fetus. This informal process means that use during pregnancy is off-label, with dosing, pharmacokinetics, pharmacodynamics, safety and efficacy not described in regulatory documents or product labels. This is a special concern owing to the complex physiological, cellular and molecular changes that occur across pregnancy. In addition, special attention must be given to the placenta owing to its role in transport between mother and fetus, and metabolism, as well as vulnerability to toxicity. This article will consider how maternal physiology changes and impacts drug disposition with emphasis on the role of the placenta in drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
